Brain Diseases  >>  Zontivity (vorapaxar)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Zontivity (vorapaxar) / Merck (MSD)
NCT00684515: Trial to Assess the Safety of Vorapaxar in Japanese Subjects With Cerebral Infarction (P05005; MK-5348-017)

Completed
2
90
NA
Vorapaxar 2.5 mg, Vorapaxar 1 mg, Placebo, Aspirin 75-150 mg
Merck Sharp & Dohme LLC
Cerebral Infarction
11/07
11/07

Download Options